AIIMS Develops Affordable CAR-T Cell Therapy for Multiple Myeloma

Sangamo Therapeutics and Astellas Collaborate on Innovative Gene Therapy for Neurological Diseases

FDA Clears IND for Arbor Biotechnologies’ ABO-101 Gene Editing Therapeutic for Primary Hyperoxaluria Type 1

Fortis Healthcare Acquires Stake in Agilus Diagnostics

FDA Approves BRAFTOVI® Combination Regimen as First-Line Treatment for BRAF V600E-Mutant Metastatic Colorectal Cancer

The Role of Big Data in Precision Medicine

Caris Life Sciences Celebrates 1,000+ Precision Medicine Studies, Advancing Cancer Research and Patient Outcomes

OncoHelix and Qualisure Diagnostics Partner to Bring Thyroid GuidePx® Test to Canadian Patients

Gates Foundation Invests $50 Million in Tessera Therapeutics to Advance Gene Therapy for Sickle Cell Disease

FDA Approves Ensartinib (Ensacove) as First-Line Treatment for ALK-Positive NSCLC

Guardant Health and Boehringer Ingelheim Collaborate to Advance Liquid Biopsy CDx for HER2-Targeted Therapy in NSCLC

Cartherics Receives $300K G-Rex Grant to Advance Cancer Cell Therapy Manufacturing

Roche Revolutionizes Mass Spectrometry Diagnostics with Launch of cobas® Mass Spec Solution

Complete Genomics Partners with Eurofins Clinical Enterprise to Expand Sequencing Service Offerings

NeuroKaire Secures $10M to Transform Precision Medicine in Psychiatry and Neurology

Home
/
update
/
details

MedGenome Names Dr. Amit Kakar as New Chairman of the Board

NextEdge Admin

11 Sep 2024

2 min 57 sec

MedGenome, a global leader in genomics-driven diagnostics and research services, has appointed Dr. Amit Kakar as Chairman of its Board, succeeding Dr. Felix Olale. Dr. Kakar, who has served on the MedGenome board since 2022, is Managing Partner and Head of Asia at Novo Holdings, a prominent life sciences investor. With over 30 years of experience in the healthcare and life sciences industries, Dr. Kakar has held senior positions at Avenue Capital, GE Healthcare, and Everlife Asia, and currently serves on the boards of Doctor Anywhere, ESCO, and Qure.ai.

Dr. Kakar brings a wealth of expertise in healthcare investments and operations, having been involved in healthcare leadership across Asia, the US, and Europe. In his new role, he will guide MedGenome’s growth strategy, emphasizing expanding its global footprint and making healthcare solutions affordable and accessible. MedGenome’s mission is to transform healthcare through its innovative genomic research and diagnostics, providing critical insights at the molecular level to diagnose complex diseases and enable advancements in precision medicine.

MedGenome is a leader in genetic testing in India, offering more than 1,300 tests across key areas such as oncology, reproductive health, inherited diseases, infectious diseases, and preventive wellness. The company has sequenced over 350,000 genomes and exomes, built a network of over 5,000 hospitals and 15,000 clinicians across India, and created the largest database of South Asian genetic variants. Its consumer-focused division, Genessense, offers preventive wellness tests aimed at understanding genetic predispositions to lifestyle diseases.

MedGenome operates globally, with the largest CAP-accredited genetic testing lab in South Asia, a high-throughput Next-Generation Sequencing lab in California, and presence in the US, India, Singapore, and Africa. Mahesh Pratapneni, MedGenome’s Group CEO and Co-founder, commended Dr. Kakar’s leadership and sector expertise, expressing confidence in his ability to lead MedGenome’s next phase of growth.